BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Storgaard L, Tran TL, Freiberg JC, Hauser AS, Kolko M. Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development. Front Med (Lausanne) 2021;8:733080. [PMID: 34589504 DOI: 10.3389/fmed.2021.733080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Pezzino S, Sofia M, Greco LP, Litrico G, Filippello G, Sarvà I, La Greca G, Latteri S. Microbiome Dysbiosis: A Pathological Mechanism at the Intersection of Obesity and Glaucoma. Int J Mol Sci 2023;24. [PMID: 36674680 DOI: 10.3390/ijms24021166] [Reference Citation Analysis]
2 Ma D, Pasquale LR, Girard MJA, Leung CKS, Jia Y, Sarunic MV, Sappington RM, Chan KC. Reverse translation of artificial intelligence in glaucoma: Connecting basic science with clinical applications. Front Ophthalmol 2023;2. [DOI: 10.3389/fopht.2022.1057896] [Reference Citation Analysis]
3 Murenu E, Gerhardt MJ, Biel M, Michalakis S. More than meets the eye: The role of microglia in healthy and diseased retina. Front Immunol 2022;13:1006897. [PMID: 36524119 DOI: 10.3389/fimmu.2022.1006897] [Reference Citation Analysis]
4 Shyamalee T, Meedeniya D. Glaucoma Detection with Retinal Fundus Images Using Segmentation and Classification. Mach Intell Res 2022. [DOI: 10.1007/s11633-022-1354-z] [Reference Citation Analysis]
5 Das A, Imanishi Y. Drug Discovery Strategies for Inherited Retinal Degenerations. Biology 2022;11:1338. [DOI: 10.3390/biology11091338] [Reference Citation Analysis]
6 Greener M. Glaucoma: pharmacological management and iatrogenic causes. Journal of Prescribing Practice 2022;4:388-394. [DOI: 10.12968/jprp.2022.4.9.388] [Reference Citation Analysis]
7 Lee D, Nakai A, Miwa Y, Tomita Y, Kunimi H, Chen J, Ikeda SI, Tsubota K, Negishi K, Kurihara T. Retinal degeneration induced in a mouse model of ischemia-reperfusion injury and its management by pemafibrate treatment. FASEB J 2022;36:e22497. [PMID: 35969144 DOI: 10.1096/fj.202200455RRR] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Vallabh NA, Armstrong J, Czanner G, Mc Donagh B, Choudhary A, Criddle DN, Willoughby CE. Evidence of impaired mitochondrial cellular bioenergetics in ocular fibroblasts derived from glaucoma patients. Free Radic Biol Med 2022:S0891-5849(22)00483-X. [PMID: 35872337 DOI: 10.1016/j.freeradbiomed.2022.07.009] [Reference Citation Analysis]
9 Wang D, Gao F, Zhang X, Hu F, Xu P, Wu J. Nobiletin protects retinal ganglion cells in models of ocular hypertension in vivo and hypoxia in vitro. Lab Invest 2022. [DOI: 10.1038/s41374-022-00813-8] [Reference Citation Analysis]
10 Vohra R, Sanz-morello B, Tams ALM, Mouhammad ZA, Freude KK, Hannibal J, Aldana BI, Bergersen LH, Kolko M. Prevention of Cell Death by Activation of Hydroxycarboxylic Acid Receptor 1 (GPR81) in Retinal Explants. Cells 2022;11:2098. [DOI: 10.3390/cells11132098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lambuk L, Mohd Lazaldin MA, Ahmad S, Iezhitsa I, Agarwal R, Uskoković V, Mohamud R. Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art. Front Pharmacol 2022;13:875662. [DOI: 10.3389/fphar.2022.875662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 AlRyalat SA, Ertel MK, Seibold LK, Kahook MY. Designs and Methodologies Used in Landmark Clinical Trials of Glaucoma: Implications for Future Big Data Mining and Actionable Disease Treatment. Front Med (Lausanne) 2022;9:818568. [PMID: 35155501 DOI: 10.3389/fmed.2022.818568] [Reference Citation Analysis]
13 Liu P, Wang F, Song Y, Wang M, Zhang X. Current situation and progress of drugs for reducing intraocular pressure. Therapeutic Advances in Chronic Disease 2022;13:204062232211403. [DOI: 10.1177/20406223221140392] [Reference Citation Analysis]